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Vanilloid receptor subunit 1 (VR1) appears to play a critical role in the
transduction of noxious chemical and thermal stimuli by sensory
nerve endings in peripheral tissues. Thus, VR1 antagonists are useful
compounds to unravel the contribution of this receptor to pain
perception, as well as to induce analgesia. We have used a combina-
torial approach to identify new, nonpeptidic channel blockers of VR1.
Screening of a library of trimers of N-alkylglycines resulted in the
identification of two molecules referred to as DD161515 {N-[2-(2-(N-
methylpyrrolidinyl)ethyl]glycyl]-[N-[2,4-dichlorophenethyl]glycyl]-
N-(2,4-dichlorophenethyl)glycinamide} and DD191515 {[N-[3-(N,N-
diethylamino)propyl]glycyl]-[N-[2,4-dichlorophenethyl]glycyl]-N-(2,4-
dichlorophenethyl)glycinamide} that selectively block VR1 channel
activity with micromolar efficacy, rivaling that characteristic of
vanilloid-related inhibitors. These compounds appear to be non-
competitive VR1 antagonists that recognize a receptor site distinct
from that of capsaicin. Intraperitoneal administration of both trial-
kylglycines into mice significantly attenuated thermal nociception as
measured in the hot plate test. It is noteworthy that these compounds
eliminated pain and neurogenic inflammation evoked by intradermal
injection of capsaicin into the animal hindpaw, as well as the thermal
hyperalgesia induced by tissue irritation with nitrogen mustard. In
contrast, responses to mechanical stimuli were not modified by either
compound. Modulation of sensory nerve fibers excitability appears
to underlie the peptoid analgesic activity. Collectively, these results
indicate that blockade of VR1 activity attenuates chemical and ther-
mal nociception and hyperalgesia, supporting the tenet that this
ionotropic receptor contributes to chemical and thermal sensitivity
and pain perception in vivo. These trialkylglycine-based, noncompet-
itive VR1 antagonists may likely be developed into analgesics to treat
inflammatory pain.
Identification and cloning of the VR1 channel represented asignificant step in the clarification of the molecular mecha-
nisms underlying transduction of noxious chemical and thermal
stimuli by peripheral nociceptors (1). This receptor is a nonse-
lective cation channel with high Ca2 permeability activated by
capsaicin and its analogues, as well as by endocannabinoids (1,
2). In addition, VR1 also is gated by noxious heat (43°C) and
low pH (3, 4). Moreover, VR1 channel activity is strongly
modulated by the action of inflammatory mediators such as
bradykinin and prostaglandins, presumably by PKC or PKA
mediated receptor phosphorylation (5, 6). There is evidence that
VR1 plays a key role in both nociception and inflammatory pain
(7, 8). Therefore, VR1 has been considered a molecular inte-
grator of noxious stimuli in the peripheral terminals of primary
sensory neurons involved in pain signaling. This tenet is also
supported by results indicating that modulators of VR1 channel
activity exhibit analgesic activity (9–11). Thus, the implication of
VR1 in pain and hyperalgesia makes this ion channel as a prime
therapeutic target for analgesic drugs.
Despite the wealth of information accrued in recent years on
VR1 function, the number of available compounds that modu-
late its activity is still quite limited (12). A significant effort has
been focused on developing competitive capsaicin antagonists
(11, 13–16). The family of noncompetitive antagonists such as
ruthenium red and arginine-rich peptides has been also consid-
ered (9, 17). Most of available substances, however, exhibit either
unwanted side effects or toxicity or metabolic instability (10, 12,
18). To address this issue, we used a combinatorial-based
approach to identify nonpeptide based VR1-specific channel
blockers such as oligo N-substituted glycines (also known as
peptoids) that exhibit high proteolytic stability (19). We identi-
fied two peptoids that appear to be noncompetitive VR1 antag-
onists. These molecules attenuated in vivo thermal nociception
and hyperalgesia, and suppressed capsaicin-evoked pain.
Methods
Synthesis of Trialkylglycines-Based Combinatorial Mixtures and Indi-
vidual Compounds. The library and individual oligo N-
alkylglycines were prepared by simultaneous multiple solid phase
synthesis (20). The mixture positions (X in Fig. 1) were incor-
porated by coupling a mixture of 22 selected amines with the
relative ratios adjusted to yield equimolar incorporation. Briefly,
starting from Rink amide resin [0.7 milliequivalent (meq)g;
Rapp Polymere, Germany] the eight-step synthetic pathway
involved the initial release of the fluorenylmethoxycarbonyl
(Fmoc) protecting group. Thereafter, the successive steps of
acylation with chloroacetyl chloride followed by the correspond-
ing amination of the chloromethyl intermediate, using the
selected individual amine (O in Fig. 1) or the mixture of amines
(X in Fig. 1), was conducted. The purity and identity of the
individual oligo N-alkylglycine active compounds was deter-
mined by analytical HPLC, laser desorption time-of-f light MS,
and 1H and 13C NMR (see Supporting Text, which is published as
supporting information on the PNAS web site, www.pnas.org).
Recombinant Rat VR1 Channels Expression in Xenopus Oocytes and
Channel Blockade. All of the procedures have been described in
detail elsewhere (9, 21, 22). Whole-cell currents from rat VR1-
injected oocytes were recorded in Mg2-Ringer’s solution (in
mM: 10 Hepes, pH 7.4115 NaCl2.8 KCl0.1 BaCl22.0 MgCl2)
with a two-microelectrode voltage-clamp amplifier at 20°C (9).
VR1 channels were activated by application of 10 M capsaicin
in absence or presence of peptoid mixtures or individual com-
pounds at a holding potential (Vh) of 80 mV. Receptor
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selectivity of identified trialkylglycines was evaluated on heter-
ologously expressed NMDA receptors (rat NR1:NR2A), and on
K (mouse Kv1.1), Na (rat SKN4A), and Ca2 (rat 1H
T-type) selective channels (see Supporting Text).
Culturing of Trigeminal Primary Sensory Neurons, Fluorimetric Ca2
Measurements, and Electrophysiological Recordings. Trigeminal pri-
mary neurons from newborn mice (P7) were cultured as de-
scribed (23). Plated trigeminal neurons appear as round-to-ovoid
cells with a variety of diameters. Intracellular Ca2measurement
was performed in single cells loaded with the acetoxymethylester
of Fura-2 (Molecular Probes) as described (23). Fluorometric
measurements were carried out using a digital imaging system,
with a cooled CCD camera (Sensys, Photometrics, Tucson, AZ)
and IMAGING WORKBENCH software (Axon Instruments, Foster
City, CA).
Action potentials were recorded with an external solution
containing (in mM) 124 NaCl, 5 KCl, 1.2 KH2PO4, 2 CaCl2, 1
MgCl2, 24 NaHCO3, and 10 glucose (pH 7.4; 95% O2 5% CO2)
at 33  1°C; and pipette solution containing (in mM) 140 KCl,
10 NaCl, 4 Mg-ATP, 0.4 Na-GTP, and 10 Hepes (pH 7.3 adjusted
with KOH). Patch-pipettes had a resistance of 3 to 4 M.
Membrane voltage was recorded with an EPC8 patch-clamp
amplifier (HEKA Electronics, LambrechtPfalz, Germany).
Rat Knee Joint Nociceptor Fiber Preparation. Adult male Wistar rats
(300–350 g) were anesthetized with thipentone (100 mgkg i.p.).
The trachea, the left femoral vein, and the femoral artery were
cannulated. Arterial blood pressure was continuously moni-
tored. An additional catheter was inserted into the right saphe-
nous artery for close intraarterial injection of substances into the
joint area. The right femur was fixed by a special grip and a pool
was formed by skin flaps and filled with warm paraffin oil. The
saphenous nerve was dissected and fine filaments were subdis-
sected from the peripheral end. Nerve fibers innervating the
knee joint were identified by the location of their receptive field,
which was determined by the firing response to probing the
structures in and around the knee joint with a hand-held glass
(24). The recordings were made in multiunit filaments contain-
ing between two and five identifiable units. The mechanical
stimuli consisted of normal and noxious outward and inward
rotation of the knee joint lasting 10 s. Activation of the units by
close intraarterial injection of KCl (0.1 mM, 0.1 ml) was used to
ascertain that solutions reached the sensory endings in the knee
joint.
Behavioral Nociception Assays. Adult male ICR mice were habit-
uated to the test environment for 24 h in Plexiglas chambers
prior the nociception assays. Thermal nociception was studied
using a hot plate at 52 or 56°C (7, 8). The response latency for
paw shaking or licking or jumping was measured. For the tail
immersion assay, the animal was gently restrained and the distal
two-thirds of the tail were immersed into a water bath at 52°C
and the latency to tail f lick recorded (7).
Mechanical nociception was evaluated using von Frey hairs as
described (25). In brief, mice were placed on a raised wire mesh
grid (6  6 mm2 apertures) under plastic chambers. To quantify
the mechanical sensitivity of the paw, hairs with different forces
(in mN) were applied ten times to the hindpaw in ascending
order of force. The frequency and intensity of responses of
withdrawal were monitored. The hair was applied for 1–2 s, with
an interstimulus interval of 5–10 s.
Capsaicin-Induced Hyperalgesia. Capsaicin (10 l at 0.06% in 10%
ethanol, 10% Tween 80, and 80% saline) was injected intrader-
mally into the heel pad with a 0.3-mm diameter needle attached
to a Hamilton syringe (25). The latency and duration times of
licking and shaking the paw in response to the injection was
recorded. The mechanical sensitivity of the plantar surface of
the injected and contralateral paw was tested again 20 min after
capsaicin or vehicle injection with von Frey hairs as described
(25). Contralateral and ipsilateral paw volumes were measured
with a plethysmometer.
Mustard Oil Thermal Hyperalgesia. Thermal sensitivity of mice was
assayed in the hot plate at 52°C. Thereafter, mustard oil (10%
in mineral oil) was painted onto both hindpaws, the animals were
injected either with saline or 0.2 mmolkg peptoid, and the hot
plate test was repeated at the indicated times.
Drug Administration. Trimers of N-alkylglycines were dissolved in
ethanol, diluted in saline at the desired concentrations (final
ethanol concentration was 1.0%), and administered i.p. The
injected volume was normalized to the animal weight.
Statistical Analysis. All results are given as mean  SEM, with n
(number of animals) 7. Data were statistically analyzed using
the unpaired t test or one-way ANOVA test.
Results
A mixture-based combinatorial library made of trimers of N-
alkylglycines in a positional scanning format was screened to
identify blockers of VR1 channel activity (Fig. 1, Top, Inset). The
library consisted of three different sublibraries, each addressing
one position of the trialkylglycine. Thus, a single position was
defined with 1 of the 22 primary amines used (O in Fig. 1), and
the remaining two positions had an equimolar mixture of these
amines (X in Fig. 1). Each mixture contained 484 molecules,
and the library chemical diversity comprised 10,648 individual
trimers.
Peptoid mixtures were assayed for blockade activity of recom-
binant VR1 channels heterologously expressed in amphibian
oocytes. Screening of the complete library identified several
mixtures that blocked by 50% the capsaicin-evoked ionic
current (Fig. 1). Based on the screening data, a family of
Fig. 1. Screening of an oligo N-substituted glycine combinatorial library to
identify VR1 channel blockers. VR1 blockade profile of the 66 library mixtures.
Each graph represents the blocking activity for each of the three positions that
compose the library. The bars denote the activity of each mixture as a function
of the number of the defined amine used to generate the chemical diversity.
Library mixtures were assayed at 100 gml. Horizontal bar denotes the
cut-off blocking activity (set to 50%). (Inset) Generic formula of the trialkyl-
glycine combinatorial library, where R1, R2, and R3 denote the sites where
chemical diversity was introduced.
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individual trialkylglycines was synthesized and assayed for VR1
blockade activity. Two compounds [N-[2-(2-(N-methylpyrrolidi-
nyl)ethyl]glycyl]-[N-[2,4-dichlorophenethyl]glycyl]-N-(2, 4-
dichlorophenethyl)glycinamide and [N-[3-(N,N-diethylamino)-
propyl]glycyl]-[N-[2,4-dichlorophenethyl]glycyl]-N-(2, 4-di-
chlorophenethyl)glycinamide (referred to as DD161515 and
DD191515, respectively) inhibited VR1 channel activity by
90% at 10 M (Fig. 2 A and B). VR1 block by these two
compounds was rapid and reversible. For peptoid DD161515,
the IC50 was 0.7  0.2 M and nH  0.9  0.2 (mean  SEM,
n  7), and for DD191515 was 2.6  0.6 M and nH 1.1  0.2
(n  3), indicating a higher blockade efficacy of compound
DD161515. The Hill coefficient of 1.0 is consistent with the
occurrence of a single binding site.
These peptoids appear to act as noncompetitive capsaicin
antagonists, as suggested by the similar capsaicin concentration
required to activate half-maximal response (EC50) in the absence
1.5  0.2 M (n  4) and in the presence 0.96  0.1 M (n 
4) of 1 M peptoid DD161515 (Fig. 2D). The Hill coefficient of
VR1 activation by capsaicin (nH  1.5  0.1) was not altered by
the presence of the peptoid (nH 1.7 0.2). Consistent with this
notion, acidification of the extracellular medium or mutation of
D646 to asparagine, a residue in the pore forming region of VR1
(26), reduced the peptoid blockade activity (see supporting
information). Notably, oligo-N-alkylglycines preferentially block
VR1 channels, as evidenced by the modest inhibition exerted on
NMDA receptors and voltage-gated channels selective for either
K or Na or Ca2 (see supporting information). Furthermore,
these compounds did not affect the duration nor amplitude of
action potentials in trigeminal primary sensory neurons (Fig.
3A). Collectively, these findings suggest that trialkylglycines are
potent, selective, noncompetitive VR1 antagonists that bind to
a receptor site distinct from the vanilloid binding site.
Because VR1 channels modulate intracellular Ca2 ([Ca2]i)
rises in neurons (1, 3–5), we evaluated whether the peptoid
DD161515 prevented the capsaicin-induced Ca2 influx in cul-
tured trigeminal neurons. To minimize the contribution of
vanilloid-evoked VR1 desensitization, we used a two consecutive
pulse protocol interspersed with washing periods. As illustrated
in Fig. 3B, capsaicin stimulation of neuronal cultures in the
presence of DD161515 did not result in a [Ca2]i increase.
Peptoid blockade of Ca2 influx was reversible, as evidenced by
the conspicuous increment of [Ca2]i elicited by a second,
consecutive capsaicin pulse after washing out DD161515. At 100
M, peptoid DD161515 blocked 90% of the capsaicin-evoked
[Ca2]i in 70% of the capsaicin-responsive neurons, whereas
it was less efficient (50%) in the remaining population of
capsaicin-sensitive neurons (Fig. 3B, Right Inset). DD161515
inhibition of Ca2 influx was specific because peptoids that do
not block VR1 channel activity, such as DD15 (N-[2,4-dichloro-
phenethyl]glycinamide), did not affect the vanilloid-evoked
Ca2-influx in trigeminal neurons (Fig. 3B, Right Inset). There-
fore, these results indicate that newly identified VR1 blockers
inhibit Ca2 entry through the receptor.
We next investigated whether trialkylglycines block VR1 chan-
nels present in polymodal endings of nociceptor nerve fibers
mediating pain, we evaluated the inhibition by compound
DD161515 of sensory discharges evoked by noxious stimulation
of the knee joint. In the median articular nerve of the rat, about
25% of the single unit, and 80% of the multiunit filaments that
discharged in response to noxious rotation of the knee joint were
additionally excited by close intraarterial injection of capsaicin
(Fig. 4A). A dose of 10 M capsaicin and prolonged intervals
Fig. 2. Trialkylglycines are noncompetitive capsaicin antagonists that block
VR1 with high efficacy. Representative blockade activity of the trialkylglycines
DD161515 (A) and DD191515 (B). Insets depict the chemical structure of both
peptoids. VR1 channels were activated by 10 M capsaicin and recorded at
80 mV. Peptoids were tested at 10 M. (C) Dose–response curves for com-
pounds DD161515 and DD191515 blockade activity of capsaicin-activated VR1
channels expressed in amphibian oocytes. Responses were normalized with
respect to that in the absence of trialkylglycines. Solid lines depict the theo-
retical fits to a Michaelis–Menten binding isotherm. Each point represents the
mean  SEM with, n  4. (D) Dose–response curves of VR1 activation by
capsaicin in the absence (DD161515) and presence (DD161515) of 1 M
peptoid. Data are mean  SEM, n  3.
Fig. 3. Effect of trialkylglycines on the action potential and capsaicin-evoked
[Ca2]i rises in cultured trigeminal neurons. (A) Action potentials elicited from
trigeminal primary neurons in the absence (control) and presence of 10 M
DD161515 in the external solution. Square pulse under the action potential
denotes the stimulation protocol under current clamp. (B) The traces show the
time course of the fluorescence ratio (F357F380) changes in the two neurons
shown in ratio images (Left Inset) of a culture with trigeminal primary sensory
neurons (n1, n2), fibroblasts, and glial cells, during exposure to capsaicin in the
presence of D161515 (Left) and after washing out the peptoid (Right). Solid
lines depict pulse duration for VR1 agonist and antagonist. (Right Inset)
Histogram representing the mean ratio between the second and first [Ca2]i
elevation to capsaicin, in the presence or absence of the indicated compound.
Peptoids were tested at 100 M, and capsaicin was used at 1 M. Control
denotes two consecutive pulses of capsaicin in the absence of peptoid. (Cal-
ibration bar of images, 10 m.)
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between injections (10–15 min) were used to prevent the well
known inactivation of sensory nerve fibers caused by repeated
application of the vanilloid. The capsaicin-evoked impulse dis-
charge was remarkably reduced by peptoid DD161515. As
illustrated in Fig. 4C, intraarterial injection of DD161515 (0.4
mol, n  3), followed by washing with saline, gradually
abolished (mean time 30 min) the impulse discharge of a
subsequent capsaicin administration (Fig. 4 B and C). This
inhibitory action was reversible, with a mean recovery time of 1 h
(Fig. 4D). In contrast, the impulse discharge evoked by mechan-
ical stimulation was virtually unaffected by administration of 0.4
mol of peptoid DD161515 (Fig. 4 E and F). Intraarterial
administration of a higher dose of peptoid (1.6 mol, n  2),
along with no washing with saline after its injection (which
increases the exposure time of nerve endings to the peptoid),
resulted in a rapid (5 min), complete and sustained (1 h)
inhibition of the capsaicin-evoked nerve responses. In these
conditions, however, a gradual attenuation of mechanically
stimulated discharges by the peptoid was also observed, suggest-
ing an unspecific effect of the peptoid at high concentrations
(data not shown). Collectively, these findings imply that newly
identified peptoids may exhibit in vivo antinociceptive orand
analgesic activity.
To address whether VR1 antagonists have antinociceptive
properties, we conducted behavioral nociception tests in animals
before and after i.p. injection of the vehicle (1% ethanol in
saline) and the trialkylglycine DD161515. First, we determined
whether these compounds modified the response to noxious heat
explored with the hot plate test. As illustrated in Fig. 5A,
compound DD161515 significantly attenuated thermal nocicep-
tion at 52°C (vehicle: 11  2 s hot plate latency, n  8) when
administered at 0.2 mmolkg (25  3 s, n  7, P 	 0.01). This
antinociceptive activity was transient, exhibiting a maximum
activity at 30 min postinjection and disappearing 2 h afterward
(Fig. 5B). Similar results were obtained with the tail immersion
test at 52°C, where peptoid DD161515 prolonged the withdrawal
latency by 40% (vehicle: 2.5  0.2 s, n  13; DD161515: 3.4 
0.2 s, n  17, P 	 0.05; Fig. 5E). Peptoid DD191515 also
displayed an analgesic effect (Fig. 5C). Overall, the thermal
antinociceptive activity of DD161515 at 52°C was higher than
that exhibited by compound DD191515, consistent with its
stronger blockade efficacy of VR1 channel activity. In contrast,
whereas peptoid DD161515 did not significantly decrease noci-
ception at 56°C, DD191515 exhibited conspicuous antinocicep-
tive activity at this temperature, as demonstrated by the 2.5-fold
increase in the hot plate latency time (vehicle: 9.5  2.1 s, n 
7; DD191515: 23.7  4.4 s, n  7, P 	 0.01; Fig. 5D). It is
noteworthy that these compounds reduced thermal nociception
without affecting mechanical sensory transduction. As displayed
in Fig. 5F, i.p. administration of 0.2 mmolkg DD161515 did
not modify the withdrawal threshold in the von Frey hairs
test. These results imply that identified trialkylglycines exhibit in
vivo thermal antinociception, substantiating the notion that
blockade of VR1 channels modulates thermal sensory transduc-
tion in vivo (7).
It should be expected that pharmacological blockade of VR1
channel activity may also reduce pain perception (4, 5). To
investigate attenuation of pain-related behavior by peptoids, we
evaluated capsaicin-induced pain and neurogenic inflammation
Fig. 4. Inhibition by the peptoid of capsaicin-evoked neural activity in knee
joint nociceptor fibers. (A–D) Instantaneous frequency of the nerve impulse
discharge evoked by intraarterial injections of 100l capsaicin, 10M (arrows)
before (A) and 15 min (B), 35 min (C), and 55 min (D) after the administration
of 100 l of a 4 mM (0.4 mol) solution of the peptoid D161515. (E and F) The
impulse discharge elicited by a 10-s knee joint rotation (starting at the arrow)
applied before injection of capsaicin and peptoid and 35 min after adminis-
tration of the peptoid (immediately before C), respectively. (Insets) A sample
record of the multiunit impulse activity evoked by capsaicin (A) and by the
mechanical stimulation (E).
Fig. 5. Identified trialkylglycines attenuate thermal nociception. Response
latencies in the hot plate at 52°C (A–C) and 56°C (D), and the tail immersion at
52°C (E) tests. (F) Response to mechanical stimulation of the hindpaw with von
Frey hairs of six intensities. Mice were monitored before (Pre i.p.) and 30 min
after i.p. injection of vehicle (saline) or 0.2 mmolkg of peptoid (unless
explicitly indicated in the figure). All data are given as mean SEM with n
9 (hot plate 52°, A–C), n  7 (hot plate 56°C), n  8 (tail immersion), and n 
9 (von Frey hairs). *, P	 0.05; **, P	 0.01—for saline versus peptoid with the
one-way ANOVA test and two tailed-unpaired t test.
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in mice by injecting 6 g of capsaicin into the hindpaw (Fig. 6;
ref. 25). Intraplantar injection of capsaicin evoked a licking and
shaking of the paw in mice. The latency and duration of this
behavior were, respectively, 20 8 s (n 12) and 37 10 s (n
12) (Fig. 6 A and B). Intraperitoneal administration of 0.2
mmolkg DD161515, 30 min before capsaicin intraplantar in-
jection, resulted in a remarkable 13-fold increase of the latency
time (269  31 s, n  7; Fig. 6A). The licking and shaking in
peptoid-treated animals were so brief that they reduced the
duration response virtually to zero (Fig. 6B). This effect was
dose-dependent, becoming evident at doses of 0.05 mmolkg
(80  5.4 s, n  7), and reaching maximum activity at 0.2
mmolkg (Fig. 6 A and B). In addition, peptoid DD161515 also
prevented the neurogenic inflammation secondary to intrader-
mal administration of capsaicin (Table 1). Similar results were
obtained for DD191515, although this compound showed
weaker analgesic activity requiring higher doses to attenuate
capsaicin-induced pain behavior (Fig. 6 A and B). As expected,
mice sensitized with capsaicin showed intense mechanical hy-
peralgesia in the treated paw (Fig. 6C). However, reduced
withdrawal thresholds to punctuate mechanical stimuli were not
modified by DD161515 (Fig. 6C), indicating that the peptoid do
not alter the capsaicin-induced mechanical hyperalgesia. This
result appears consistent with the lack of effect of the peptoid on
the impulse discharge evoked by mechanical stimulation of
nociceptor nerve endings (Fig. 4 E and F).
We also evaluated whether compound DD161515 attenuates
the thermal hyperalgesia provoked by application of mustard oil
to the plantar hind paw. As shown in Fig. 6D, 30 min after tissue
damage animals treated with saline exhibited a decrease in
latency of 70% (10.9 1.2 s basal vs. 3.8 0.8 s mustard oil, n
7), whereas mice injected with 0.2 mmolkg DD161515 showed
a significantly lower change of withdrawal latency (10.9  0.9 s
basal vs. 7.2  0.9 s mustard oil, n  7). Thus, trialkylglycines
attenuated capsaicin-evoked pain and neurogenic edema, as well
as thermal hyperalgesia induced by tissue irritation, without
modifying the mechanical hypersensitivity. Altogether, these
results suggest that VR1 channels contribute to chemical and
thermal hyperalgesia in vivo.
Discussion
VR1 channels have been implicated in pain detection, making
them prime therapeutic marks for target-oriented novel analge-
sic molecules (4, 7, 8). We screened a restricted, oligo N-
substituted glycine-based combinatorial library to find previ-
ously uncharacterized VR1 blockers. Oligomers of N-substituted
glycines provide a class of small, non-natural molecules that are
proteolytically stable and have potent biological activities (27).
A major advantage of using short oligomers is that low molecular
mass molecules (600 Da) usually display acceptable tissue
penetration properties and better pharmacological conformities
(28–30). The salient contribution of this work is the identifica-
tion of two VR1 antagonists that modulate nociceptive responses
to heat and substantially attenuated capsaicin-evoked pain,
thermal hyperalgesia and neurogenic edema in vivo, without
modifying the threshold to noxious mechanical stimuli. Both
peptoids are a previously uncharacterized class of molecules that
efficiently antagonize VR1 function, thus attenuating Ca2
influx through this receptor. Their blockade efficacy rivals with
that exhibited by the vanilloid-like molecule capsazepine and
VR1 channel blockers such as ruthenium red and arginine-rich
peptides. Structurally, trialkylglycine-based VR1 blockers do not
have a recognizable vanillyl-like motif, suggesting that they do
not compete for the vanilloid binding site. Indeed, our findings
indicate that identified peptoids bind to a different receptor site
than capsaicin. Structure–function studies should uncover the
molecular determinants that define this drug binding site on
VR1 channels.
The role of VR1 channels in nociception and pain perception
has been a matter of intense investigation. Genetic ablation of
these channels proved their role in inflammatory pain signaling
and thermal and chemical hyperalgesia but not in mechanical
hyperalgesia (7, 8). Our findings substantiate this observation in
that they show that pharmacological suppression of VR1 activity
abolished vanilloid-evoked inflammation and attenuated hyper-
algesia to thermal stimuli secondary to tissue irritation. Intrigu-
ingly, the contribution of VR1 subunits to thermal nociception
is more controversial. Whereas the group of Caterina et al. (7)
found robust deficits in thermally evoked pain in their VR1-null
animals, Davis et al. (8) did not observe significant alterations in
the responses to acute noxious thermal stimuli in their strain of
VR1-knock out mice. This discrepancy may arise from the
different mouse strains used in these studies. Our data, however,
are in agreement with the findings of Caterina et al. and support
that VR1 is a sensor for commonly encountered noxious thermal
stimuli (4). As shown, both peptoids significantly prolonged the
mean latency of the response to heating the plate at 52°C.
Interestingly, peptoid DD161515 specifically attenuated the
response at 52°C, whereas compound DD191515 reduced the
Fig. 6. Selected trialkylglycines ablate capsaicin-evoked inflammation and
thermal hyperalgesia. Latency to first action (A) and duration of action (B) of
the behavioral reaction (licking and shaking paw) evoked by intraplantar
injection of capsaicin in the absence (saline) or presence of trialkylglycines. (C)
Responses to mechanical stimulation of the hindpaw with von Frey hairs. Mice
were tested 60 min after i.p. injection of saline or 0.2 mmolkg DD161515
(Capsaicin). Thereafter, capsaicin (6g) was intradermally administered into
one hindpaw of the same animals, which were tested 30 min later (Capsa-
icin). (D) Change in hot-plate latency after painting the plantar hindpaw with
10% mustard oil (n 7). All data are given as mean SEM with n 9 (A and
B) or n 7 (C and D). *, P	 0.05; **, P	 0.01—for saline versus peptoid with
the one-way ANOVA test and two tailed-unpaired t test.
Table 1. Trialkylglycines reduce capsaicin-induced
neurogenic inflammation
Paw volumes, mm3
Contralateral Ipsilateral
Saline DD161515 15.1  1.4 20.6  2.0*
0.05 mmolKg 12.8  1.2 15.3  1.1
0.2 mmolKg 13.0  1.3 15.2  1.6
Peptoids or saline (1% ethanol) were injected intraperitoneally. Capsaicin
(6 g) was intradermally administered into the ipsilateral hindpaw of the
animals. Paw volumes were measured with a plethysmometer. Data are given
as mean SEM with n9. *, P	0.001 for contralateral vs. ipsilateral paw with
the one-way ANOVA test.
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heat-evoked response at both 52°C and 56°C. These results
suggest that the analgesic effect of DD161515 is mediated by
modulation of the low-threshold heat channel (43°C)—i.e.,
VR1 (4). In contrast, peptoid DD191515 might also block a
high-threshold heat channel such as VRL-1 (52°C; ref. 31) or,
alternatively, a yet unrecognized protein. As in VR1-null mice,
we also observed larger heat-evoked behavioral deficits in the
hot plate than in the tail immersion, consistent with the inter-
pretation that VR1 does not contribute equally to all forms of
thermal nociception (4, 7). The in vivo analgesic activity exerted
by these compounds appears to result primarily from a reduced
responsiveness of sensory nerve endings in peripheral tissues.
Collectively, these results highlight a major role of VR1 in the
onset of nociceptive responses to heat and in primary hyperal-
gesia elicited by tissue damage, thus underscoring its interest as
a therapeutic target for treating specific types of pain.
The extent of antinociceptive and analgesic activities of newly
identified trialkylglycines blockers was comparable to that dis-
played by vanilloid-like molecules (10, 11). It should be noted,
however, that doses 0.05 mmolkg for attenuation of periph-
eral nociceptor activity and antiinflammatory effects and as high
as 0.2 mmolkg were required to decrease thermal nociception
and hyperalgesia. These therapeutic amounts contrast with the
peptoids micromolar blocking efficacy of VR1 channel activity
in vitro, suggesting a poor absorptiondelivery andor extensive
metabolism. The short duration of the response (1 h) appears
consistent with this notion. In analogy to vanilloids, the hydro-
phobic nature of both peptoids (logP  5.0) could hamper their
in vivo effectiveness (29, 30). The route of administration, which
is influenced by the physicochemical characteristics of the
molecules, may have also contributed to the low bioavailability
observed. For example, i.p. and transdermal administration
appears to be better suited for hydrophilic molecules than for
hydrophobic compounds. Indeed, vanilloid-like molecules with
improved water solubility exhibit enhanced absorptiondelivery
and metabolic stability resulting in higher antinociception (10,
11). Accordingly, chemical modifications aimed at reducing the
hydrophobicity of both trialkylglycines, without altering the
pharmacophore identity or significantly increasing their molec-
ular mass, should enhance their therapeutic index. Thus, these
peptoids may be considered leads for drug development. At
variance with vanilloid-like molecules, trialkylglycines should not
exhibit excitatory nor cytotoxic properties because they do not
activate the VR1 channel.
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